Entrada Therapeutics (TRDA) Asset Utilization Ratio (2023 - 2026)

Entrada Therapeutics' Asset Utilization Ratio history runs 4 years deep, the most recent figure standing at 0.02 for Q1 2026.

• On a quarterly basis, Asset Utilization Ratio fell 95.27% year-over-year to 0.02 in Q1 2026; TTM through Mar 2026 was 0.02, a 95.27% decrease from a year earlier, with the FY2025 full-year figure at 0.06, down 86.71% from the prior year.
• Asset Utilization Ratio retreated to 0.02 in Q1 2026 per TRDA's latest filing, from 0.06 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.44 in Q2 2024 and bottomed at 0.02 in Q1 2026.
• The 4-year median for Asset Utilization Ratio is 0.18 (2023), against an average of 0.22.
• Across the five-year window, Asset Utilization Ratio jumped 389.05% in 2024 and tumbled 95.27% in 2026, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.27 in 2023, then jumped by 44.23% to 0.39 in 2024, then tumbled by 83.5% to 0.06 in 2025, then tumbled by 74.98% to 0.02 in 2026.
• Per Business Quant, the three latest TRDA Asset Utilization Ratio figures stand at 0.02 (Q1 2026), 0.06 (Q4 2025), and 0.14 (Q3 2025).